Home   >  
Cell Cycle/DNA Damage
  >  
CDK

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

CDK

Chemical Structure Cat. No. Product Name CAS No.
bio-THZ1 Chemical Structure
BCP44798 bio-THZ1 1604811-14-4
bio-THZ1 is a biotinylated version of THZ1 and binds irreversibly to CDK7.
Ebvaciclib Chemical Structure
BCP35102 Ebvaciclib 2185857-97-8
Ebvaciclib is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.
Abemaciclib Metabolites M2 Chemical Structure
BCP42813 Abemaciclib Metabolites M2 1231930-57-6
Abemaciclib Metabolites M2 is a metabolite of abemaciclib, acts as a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anti-cancer activity.
CDK4/6/1 Inhibitor Chemical Structure
BCP43972 CDK4/6/1 Inhibitor 2099128-41-1
CDK4/6/1 Inhibitor is a CDK4/6 inhibitor. It is a potent anti-proliferative agent that arrests U87MG cell line exclusively in G1.
CLK-IN-T3 Chemical Structure
BCP43827 CLK-IN-T3 2109805-56-1
CLK-IN-T3 is a pan-CLK inhibitor, CLK-IN-T3 as well as the negative control T3-CLK-N have been developed in collaboration with Takeda 3 (5).
Indirubin-3'-oxime Chemical Structure
BCP43705 Indirubin-3'-oxime 667463-82-3
Indirubin-3'-monoxime, a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes.
PF07104091 Chemical Structure
BCP42948 PF07104091 2460249-19-6
PF-07104091 is an orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity.
LY3405105 Chemical Structure
BCP42676 LY3405105 2326428-25-3
LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.
MS140 Chemical Structure
BCP42677 MS140 2229974-83-6
MS140 is a specific and highly potent CDK4/6 kinase inhibitor and also a CDK4/6 degrader (PROTAC).
SB1317 Chemical Structure
BCP42651 SB1317 1204918-72-8
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.
123下一页末页共 129 条记录 1 / 13 页 
0086-15971444841